Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy

A multicenter analysis

Masanori Kobayashi, Shigetaka Shimodaira, Kazuhiro Nagai, Masahiro Ogasawara, Hidenori Takahashi, Hirofumi Abe, Mitsugu Tanii, Masato Okamoto, Sun Ichi Tsujitani, Seiichi Yusa, Takefumi Ishidao, Junji Kishimoto, Yuta Shibamoto, Masaki Nagaya, Yoshikazu Yonemitsu

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: Dendritic cell (DC)-based cancer vaccines may have a significant benefit to patients with advanced pancreatic cancer. However, variations among clinical studies make it difficult to compare clinical outcomes. Here, we identified factors that determined the clinical benefits by analyzing data obtained at seven Japanese institutions that employed the same DC preparation and treatment regimens. Methods: Of 354 patients who met the inclusion criteria, 255 patients who received standard chemotherapy combined with peptide-pulsed DC vaccines were analyzed. Results: The mean survival time from diagnosis was 16.5 months (95 % CI 14.4-18.5) and that from the first vaccination was 9.9 months (95 % CI 8.0-12.9). Known prognostic baseline factors related to advanced pancreatic cancer, namely ECOG-PS, peritoneal metastasis, liver metastasis, and the prognostic nutrition index, were also representative. Importantly, we found that erythema reaction after vaccination was an independent and treatment-related prognostic factor for better survival and that OK-432 might be a good adjuvant enhancing the antitumor immunity during DC vaccination. Conclusions: This is the first report of a multicenter clinical study suggesting the feasibility and possible clinical benefit of an add-on DC vaccine in patients with advanced pancreatic cancer who are undergoing chemotherapy. These findings need to be addressed in well-controlled prospective randomized trials.

Original languageEnglish
Pages (from-to)797-806
Number of pages10
JournalCancer Immunology, Immunotherapy
Volume63
Issue number8
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Pancreatic Neoplasms
Dendritic Cells
Vaccines
Drug Therapy
Vaccination
Picibanil
Neoplasm Metastasis
Nutrition Assessment
Cancer Vaccines
Erythema
Multicenter Studies
Immunity
Survival Rate
Randomized Controlled Trials
Peptides
Survival
Liver
Therapeutics
Clinical Studies

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy : A multicenter analysis. / Kobayashi, Masanori; Shimodaira, Shigetaka; Nagai, Kazuhiro; Ogasawara, Masahiro; Takahashi, Hidenori; Abe, Hirofumi; Tanii, Mitsugu; Okamoto, Masato; Tsujitani, Sun Ichi; Yusa, Seiichi; Ishidao, Takefumi; Kishimoto, Junji; Shibamoto, Yuta; Nagaya, Masaki; Yonemitsu, Yoshikazu.

In: Cancer Immunology, Immunotherapy, Vol. 63, No. 8, 01.01.2014, p. 797-806.

Research output: Contribution to journalArticle

Kobayashi, M, Shimodaira, S, Nagai, K, Ogasawara, M, Takahashi, H, Abe, H, Tanii, M, Okamoto, M, Tsujitani, SI, Yusa, S, Ishidao, T, Kishimoto, J, Shibamoto, Y, Nagaya, M & Yonemitsu, Y 2014, 'Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: A multicenter analysis', Cancer Immunology, Immunotherapy, vol. 63, no. 8, pp. 797-806. https://doi.org/10.1007/s00262-014-1554-7
Kobayashi, Masanori ; Shimodaira, Shigetaka ; Nagai, Kazuhiro ; Ogasawara, Masahiro ; Takahashi, Hidenori ; Abe, Hirofumi ; Tanii, Mitsugu ; Okamoto, Masato ; Tsujitani, Sun Ichi ; Yusa, Seiichi ; Ishidao, Takefumi ; Kishimoto, Junji ; Shibamoto, Yuta ; Nagaya, Masaki ; Yonemitsu, Yoshikazu. / Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy : A multicenter analysis. In: Cancer Immunology, Immunotherapy. 2014 ; Vol. 63, No. 8. pp. 797-806.
@article{1a47002aeace4f0f80dcac05b9faf738,
title = "Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: A multicenter analysis",
abstract = "Objective: Dendritic cell (DC)-based cancer vaccines may have a significant benefit to patients with advanced pancreatic cancer. However, variations among clinical studies make it difficult to compare clinical outcomes. Here, we identified factors that determined the clinical benefits by analyzing data obtained at seven Japanese institutions that employed the same DC preparation and treatment regimens. Methods: Of 354 patients who met the inclusion criteria, 255 patients who received standard chemotherapy combined with peptide-pulsed DC vaccines were analyzed. Results: The mean survival time from diagnosis was 16.5 months (95 {\%} CI 14.4-18.5) and that from the first vaccination was 9.9 months (95 {\%} CI 8.0-12.9). Known prognostic baseline factors related to advanced pancreatic cancer, namely ECOG-PS, peritoneal metastasis, liver metastasis, and the prognostic nutrition index, were also representative. Importantly, we found that erythema reaction after vaccination was an independent and treatment-related prognostic factor for better survival and that OK-432 might be a good adjuvant enhancing the antitumor immunity during DC vaccination. Conclusions: This is the first report of a multicenter clinical study suggesting the feasibility and possible clinical benefit of an add-on DC vaccine in patients with advanced pancreatic cancer who are undergoing chemotherapy. These findings need to be addressed in well-controlled prospective randomized trials.",
author = "Masanori Kobayashi and Shigetaka Shimodaira and Kazuhiro Nagai and Masahiro Ogasawara and Hidenori Takahashi and Hirofumi Abe and Mitsugu Tanii and Masato Okamoto and Tsujitani, {Sun Ichi} and Seiichi Yusa and Takefumi Ishidao and Junji Kishimoto and Yuta Shibamoto and Masaki Nagaya and Yoshikazu Yonemitsu",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00262-014-1554-7",
language = "English",
volume = "63",
pages = "797--806",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "8",

}

TY - JOUR

T1 - Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy

T2 - A multicenter analysis

AU - Kobayashi, Masanori

AU - Shimodaira, Shigetaka

AU - Nagai, Kazuhiro

AU - Ogasawara, Masahiro

AU - Takahashi, Hidenori

AU - Abe, Hirofumi

AU - Tanii, Mitsugu

AU - Okamoto, Masato

AU - Tsujitani, Sun Ichi

AU - Yusa, Seiichi

AU - Ishidao, Takefumi

AU - Kishimoto, Junji

AU - Shibamoto, Yuta

AU - Nagaya, Masaki

AU - Yonemitsu, Yoshikazu

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective: Dendritic cell (DC)-based cancer vaccines may have a significant benefit to patients with advanced pancreatic cancer. However, variations among clinical studies make it difficult to compare clinical outcomes. Here, we identified factors that determined the clinical benefits by analyzing data obtained at seven Japanese institutions that employed the same DC preparation and treatment regimens. Methods: Of 354 patients who met the inclusion criteria, 255 patients who received standard chemotherapy combined with peptide-pulsed DC vaccines were analyzed. Results: The mean survival time from diagnosis was 16.5 months (95 % CI 14.4-18.5) and that from the first vaccination was 9.9 months (95 % CI 8.0-12.9). Known prognostic baseline factors related to advanced pancreatic cancer, namely ECOG-PS, peritoneal metastasis, liver metastasis, and the prognostic nutrition index, were also representative. Importantly, we found that erythema reaction after vaccination was an independent and treatment-related prognostic factor for better survival and that OK-432 might be a good adjuvant enhancing the antitumor immunity during DC vaccination. Conclusions: This is the first report of a multicenter clinical study suggesting the feasibility and possible clinical benefit of an add-on DC vaccine in patients with advanced pancreatic cancer who are undergoing chemotherapy. These findings need to be addressed in well-controlled prospective randomized trials.

AB - Objective: Dendritic cell (DC)-based cancer vaccines may have a significant benefit to patients with advanced pancreatic cancer. However, variations among clinical studies make it difficult to compare clinical outcomes. Here, we identified factors that determined the clinical benefits by analyzing data obtained at seven Japanese institutions that employed the same DC preparation and treatment regimens. Methods: Of 354 patients who met the inclusion criteria, 255 patients who received standard chemotherapy combined with peptide-pulsed DC vaccines were analyzed. Results: The mean survival time from diagnosis was 16.5 months (95 % CI 14.4-18.5) and that from the first vaccination was 9.9 months (95 % CI 8.0-12.9). Known prognostic baseline factors related to advanced pancreatic cancer, namely ECOG-PS, peritoneal metastasis, liver metastasis, and the prognostic nutrition index, were also representative. Importantly, we found that erythema reaction after vaccination was an independent and treatment-related prognostic factor for better survival and that OK-432 might be a good adjuvant enhancing the antitumor immunity during DC vaccination. Conclusions: This is the first report of a multicenter clinical study suggesting the feasibility and possible clinical benefit of an add-on DC vaccine in patients with advanced pancreatic cancer who are undergoing chemotherapy. These findings need to be addressed in well-controlled prospective randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=84906790973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906790973&partnerID=8YFLogxK

U2 - 10.1007/s00262-014-1554-7

DO - 10.1007/s00262-014-1554-7

M3 - Article

VL - 63

SP - 797

EP - 806

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 8

ER -